Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.17
ALR's Cash-to-Debt is ranked lower than
87% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. ALR: 0.17 )
Ranked among companies with meaningful Cash-to-Debt only.
ALR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.14 Max: 1.88
Current: 0.17
0.08
1.88
Equity-to-Asset 0.32
ALR's Equity-to-Asset is ranked lower than
84% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ALR: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
ALR' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.35 Max: 0.77
Current: 0.32
-0.49
0.77
Debt-to-Equity 1.65
ALR's Debt-to-Equity is ranked lower than
93% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. ALR: 1.65 )
Ranked among companies with meaningful Debt-to-Equity only.
ALR' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.59  Med: 0.93 Max: 4.08
Current: 1.65
-7.59
4.08
Debt-to-EBITDA 13.68
ALR's Debt-to-EBITDA is ranked lower than
97% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. ALR: 13.68 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ALR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -21.04  Med: 6.78 Max: 13.68
Current: 13.68
-21.04
13.68
Piotroski F-Score: 4
Altman Z-Score: 0.80
Beneish M-Score: -2.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -3.00
ALR's Operating Margin % is ranked lower than
56% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. ALR: -3.00 )
Ranked among companies with meaningful Operating Margin % only.
ALR' s Operating Margin % Range Over the Past 10 Years
Min: -44.13  Med: 3.88 Max: 7.6
Current: -3
-44.13
7.6
Net Margin % -10.71
ALR's Net Margin % is ranked lower than
57% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. ALR: -10.71 )
Ranked among companies with meaningful Net Margin % only.
ALR' s Net Margin % Range Over the Past 10 Years
Min: -47.2  Med: -3.08 Max: 8.29
Current: -10.71
-47.2
8.29
ROE % -14.34
ALR's ROE % is ranked lower than
57% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. ALR: -14.34 )
Ranked among companies with meaningful ROE % only.
ALR' s ROE % Range Over the Past 10 Years
Min: -34.13  Med: -4.53 Max: 9.2
Current: -14.34
-34.13
9.2
ROA % -4.38
ALR's ROA % is ranked lower than
52% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. ALR: -4.38 )
Ranked among companies with meaningful ROA % only.
ALR' s ROA % Range Over the Past 10 Years
Min: -15.33  Med: -1.1 Max: 3.23
Current: -4.38
-15.33
3.23
ROC (Joel Greenblatt) % -7.21
ALR's ROC (Joel Greenblatt) % is ranked lower than
51% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. ALR: -7.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -169.25  Med: 9.18 Max: 22.61
Current: -7.21
-169.25
22.61
3-Year Revenue Growth Rate -5.10
ALR's 3-Year Revenue Growth Rate is ranked lower than
72% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. ALR: -5.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 8.2 Max: 73
Current: -5.1
-8.6
73
3-Year EBITDA Growth Rate -17.50
ALR's 3-Year EBITDA Growth Rate is ranked lower than
78% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. ALR: -17.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.2  Med: 6.3 Max: 102.9
Current: -17.5
-39.2
102.9
3-Year EPS without NRI Growth Rate 23.10
ALR's 3-Year EPS without NRI Growth Rate is ranked higher than
74% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ALR: 23.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.2  Med: -9.3 Max: 76.1
Current: 23.1
-57.2
76.1
GuruFocus has detected 5 Warning Signs with Alere Inc ALR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALR's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

ALR Guru Trades in Q4 2016

Eric Mindich 1,000 sh (New)
Joel Greenblatt 123,245 sh (New)
Leucadia National 40,000 sh (New)
George Soros 5,300 sh (New)
Jim Simons 76,000 sh (New)
First Eagle Investment 1,663,161 sh (+42.48%)
Jeremy Grantham 476,484 sh (+21.86%)
Diamond Hill Capital 2,424,257 sh (+4.81%)
Steven Cohen Sold Out
John Burbank Sold Out
Private Capital 759,047 sh (-8.65%)
Mario Gabelli 380,545 sh (-12.85%)
Keeley Asset Management Corp 403,105 sh (-13.12%)
» More
Q1 2017

ALR Guru Trades in Q1 2017

David Einhorn 1,046,697 sh (New)
Jim Simons 493,324 sh (+549.11%)
Jeremy Grantham 899,800 sh (+88.84%)
Diamond Hill Capital 2,424,801 sh (+0.02%)
Leucadia National 40,000 sh (unchged)
George Soros Sold Out
Eric Mindich Sold Out
Private Capital 752,917 sh (-0.81%)
Mario Gabelli 367,120 sh (-3.53%)
Joel Greenblatt 103,912 sh (-15.69%)
First Eagle Investment 1,372,088 sh (-17.50%)
» More
Q2 2017

ALR Guru Trades in Q2 2017

Steven Cohen 24,400 sh (New)
Jim Simons 2,231,924 sh (+352.43%)
Mario Gabelli 509,952 sh (+38.91%)
First Eagle Investment Sold Out
Leucadia National Sold Out
Jeremy Grantham Sold Out
David Einhorn Sold Out
Private Capital 736,260 sh (-2.21%)
Diamond Hill Capital 2,115,775 sh (-12.74%)
Joel Greenblatt 89,070 sh (-14.28%)
» More
Q3 2017

ALR Guru Trades in Q3 2017

Prem Watsa 365,000 sh (New)
Jim Simons 2,253,341 sh (+0.96%)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Diamond Hill Capital Sold Out
Private Capital 689,285 sh (-6.38%)
Mario Gabelli 454,922 sh (-10.79%)
» More
» Details

Insider Trades

Latest Guru Trades with ALR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Private Capital 2017-09-30 Reduce -6.38%0.38%$47.5 - $50.74 $ 50.992%689,285
Mario Gabelli 2017-09-30 Reduce -10.79%0.02%$47.5 - $50.74 $ 50.992%454,922
Prem Watsa 2017-09-30 New Buy1.52%$47.5 - $50.74 $ 50.992%365,000
Joel Greenblatt 2017-09-30 Sold Out 0.06%$47.5 - $50.74 $ 50.992%0
Private Capital 2017-06-30 Reduce -2.21%0.1%$39.7 - $50.29 $ 50.996%736,260
Mario Gabelli 2017-06-30 Add 38.91%0.04%$39.7 - $50.29 $ 50.996%509,952
Joel Greenblatt 2017-06-30 Reduce -14.28%0.01%$39.7 - $50.29 $ 50.996%89,070
David Einhorn 2017-06-30 Sold Out 0.58%$39.7 - $50.29 $ 50.996%0
Leucadia National 2017-06-30 Sold Out 0.13%$39.7 - $50.29 $ 50.996%0
First Eagle Investment 2017-06-30 Sold Out 0.13%$39.7 - $50.29 $ 50.996%0
First Eagle Investment 2017-03-31 Reduce -17.50%0.03%$37 - $40.65 $ 50.9931%1,372,088
David Einhorn 2017-03-31 New Buy0.58%$37 - $40.65 $ 50.9931%1,046,697
Private Capital 2017-03-31 Reduce -0.81%0.04%$37 - $40.65 $ 50.9931%752,917
Mario Gabelli 2017-03-31 Reduce -3.53%$37 - $40.65 $ 50.9931%367,120
Joel Greenblatt 2017-03-31 Reduce -15.69%0.01%$37 - $40.65 $ 50.9931%103,912
George Soros 2017-03-31 Sold Out 0.01%$37 - $40.65 $ 50.9931%0
First Eagle Investment 2016-12-31 Add 42.48%0.05%$34.83 - $45.09 $ 50.9926%1,663,161
Private Capital 2016-12-31 Reduce -8.65%0.46%$34.83 - $45.09 $ 50.9926%759,047
Keeley Asset Management Corp 2016-12-31 Reduce -13.12%0.11%$34.83 - $45.09 $ 50.9926%403,105
Mario Gabelli 2016-12-31 Reduce -12.85%0.02%$34.83 - $45.09 $ 50.9926%380,545
Joel Greenblatt 2016-12-31 New Buy0.06%$34.83 - $45.09 $ 50.9926%123,245
Leucadia National 2016-12-31 New Buy0.16%$34.83 - $45.09 $ 50.9926%40,000
George Soros 2016-12-31 New Buy0.01%$34.83 - $45.09 $ 50.9926%5,300
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB402.002.993 % Conv Perp Pfd Shs Series -B-

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NAS:PRXL, NAS:VWR, XTER:AFX, NAS:BRKR, MIL:DIA, NAS:DXCM, NAS:PRAH, NYSE:CRL, SHSE:603658, NAS:NEOG, NAS:INCR, BSP:FLRY3, NAS:EXAS, TSE:4544, BSP:DASA3, XTER:SRT3, NAS:MYGN, NAS:ICLR, SZSE:300244, NYSE:BIO » details
Traded in other countries:IM5.Germany,
Headquarter Location:USA
Alere Inc provides rapid diagnostics at the point of care, with a focus on cardio metabolic disease, infectious disease and toxicology. The Company's business segments are professional diagnostics, consumer diagnostics, and corporate and other.

Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.

Top Ranked Articles about Alere Inc

Watsa Buys 19 Holdings in What He Calls ‘Stock-Picker’s Market’ Watsa said he's also prepared for a 'hard market' ahead
As many of his peers such as Seth Klarman (Trades, Portfolio) take cover from the heated market, Prem Watsa (Trades, Portfolio) has acquired 19 new positions in the third quarter, selling none of his existing holdings and reducing only three. Read more...
Lifshitz & Miller LLP Announces Investigation of Alere Inc., Emergent BioSolutions, Inc., Frontier Communications Corporation, HSN, Inc., Insys Therapeutics Inc., LSB Industries, Inc. and Otonomy, Inc.
Alere Receives FDA Clearance for Alere™ i Influenza A & B 2 Rapid Molecular Test
Alere Announces the U.S. Department of Justice Closes Investigation
Alere Reaches Settlement With SEC The company will pay $13 million
Alere Inc. (NYSE:ALR) announced Sept. 28 it has settled with the U.S. Securities and Exchange Commission in regard to an investagion of accounting issues concerning the company's foreign subsidiaries. Read more...
Abbott Acquisition of Alere Set to Close on October 3, 2017
Alere Announces Agreement in Principle to Settle with the U.S. Department of Justice
Alere Announces Settlement with SEC
Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock
Alere Announces Intent to Voluntarily Delist Series B Convertible Perpetual Preferred Stock from the NYSE Conditioned Upon the Completion of its Acquisition by Abbott

Ratios

vs
industry
vs
history
Forward PE Ratio 23.36
ALR's Forward PE Ratio is ranked lower than
55% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.26 vs. ALR: 23.36 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 309.03
ALR's Price-to-Owner-Earnings is ranked lower than
96% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.21 vs. ALR: 309.03 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.13  Med: 23.61 Max: 3107.86
Current: 309.03
9.13
3107.86
PB Ratio 3.86
ALR's PB Ratio is ranked higher than
52% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. ALR: 3.86 )
Ranked among companies with meaningful PB Ratio only.
ALR' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 1.74 Max: 3.86
Current: 3.86
0.42
3.86
PS Ratio 1.91
ALR's PS Ratio is ranked higher than
73% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. ALR: 1.91 )
Ranked among companies with meaningful PS Ratio only.
ALR' s PS Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.42 Max: 4.22
Current: 1.91
0.52
4.22
Price-to-Free-Cash-Flow 131.76
ALR's Price-to-Free-Cash-Flow is ranked lower than
92% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. ALR: 131.76 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.03  Med: 20.3 Max: 168.64
Current: 131.76
7.03
168.64
Price-to-Operating-Cash-Flow 47.61
ALR's Price-to-Operating-Cash-Flow is ranked lower than
83% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. ALR: 47.61 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.63  Med: 11.97 Max: 53.06
Current: 47.61
4.63
53.06
EV-to-EBIT -138.41
ALR's EV-to-EBIT is ranked lower than
99.99% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. ALR: -138.41 )
Ranked among companies with meaningful EV-to-EBIT only.
ALR' s EV-to-EBIT Range Over the Past 10 Years
Min: -676  Med: 45.9 Max: 639.4
Current: -138.41
-676
639.4
EV-to-EBITDA 35.26
ALR's EV-to-EBITDA is ranked lower than
76% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. ALR: 35.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -173.6  Med: 13.9 Max: 87.3
Current: 35.26
-173.6
87.3
EV-to-Revenue 3.21
ALR's EV-to-Revenue is ranked higher than
58% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. ALR: 3.21 )
Ranked among companies with meaningful EV-to-Revenue only.
ALR' s EV-to-Revenue Range Over the Past 10 Years
Min: 2  Med: 2.8 Max: 6.1
Current: 3.21
2
6.1
Current Ratio 2.04
ALR's Current Ratio is ranked lower than
62% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. ALR: 2.04 )
Ranked among companies with meaningful Current Ratio only.
ALR' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.78 Max: 3.42
Current: 2.04
0.7
3.42
Quick Ratio 1.54
ALR's Quick Ratio is ranked lower than
65% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. ALR: 1.54 )
Ranked among companies with meaningful Quick Ratio only.
ALR' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.36 Max: 2.89
Current: 1.54
0.46
2.89
Days Inventory 95.83
ALR's Days Inventory is ranked lower than
54% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.37 vs. ALR: 95.83 )
Ranked among companies with meaningful Days Inventory only.
ALR' s Days Inventory Range Over the Past 10 Years
Min: 80.56  Med: 93.18 Max: 104.46
Current: 95.83
80.56
104.46
Days Sales Outstanding 59.13
ALR's Days Sales Outstanding is ranked higher than
57% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. ALR: 59.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.13  Med: 67.28 Max: 79.93
Current: 59.13
59.13
79.93
Days Payable 65.70
ALR's Days Payable is ranked higher than
54% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. ALR: 65.70 )
Ranked among companies with meaningful Days Payable only.
ALR' s Days Payable Range Over the Past 10 Years
Min: 45.36  Med: 53.06 Max: 65.7
Current: 65.7
45.36
65.7

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 0.50
ALR's 5-Year Yield-on-Cost % is ranked lower than
85% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. ALR: 0.50 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.5
3-Year Average Share Buyback Ratio -2.00
ALR's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. ALR: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -60.8  Med: -3.4 Max: 19.3
Current: -2
-60.8
19.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.71
ALR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
58% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. ALR: 1.71 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.45  Med: 1.22 Max: 6.82
Current: 1.71
0.45
6.82
Price-to-Median-PS-Value 1.35
ALR's Price-to-Median-PS-Value is ranked lower than
66% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ALR: 1.35 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 1 Max: 2.87
Current: 1.35
0.36
2.87
Earnings Yield (Greenblatt) % -0.72
ALR's Earnings Yield (Greenblatt) % is ranked higher than
50% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. ALR: -0.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19.4  Med: 1.2 Max: 3.1
Current: -0.72
-19.4
3.1
Forward Rate of Return (Yacktman) % -7.16
ALR's Forward Rate of Return (Yacktman) % is ranked lower than
86% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.99 vs. ALR: -7.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -7.2  Med: 3.4 Max: 10.8
Current: -7.16
-7.2
10.8

More Statistics

Revenue (TTM) (Mil) $2,332.93
EPS (TTM) $ -3.12
Short Percentage of Float8.53%
52-Week Range $34.41 - 51.00
Shares Outstanding (Mil)87.58

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 2,439 2,501
EPS ($) 2.06 2.18
EPS without NRI ($) 2.06 2.18
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.80%
Dividends per Share ($) 0.25

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}